Clinical trial

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

NCT03448458

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

PROCEDURE · Unmapped registry intervention CT (Computed Tomography) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Gallium Ga 68-DOTATATE Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Positron Emission Tomography Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-02-22

PhasePHASE2

Conditions

Castration-Resistant Prostate Carcinomaverified · MONDO: castration-resistant prostate carcinoma

Metastatic Prostate Carcinomaverified · MONDO: metastatic prostate carcinoma

Stage IV Prostate Cancer AJCC v7unresolved

Interventions

CT (Computed Tomography)PROCEDURE

Gallium Ga 68-DOTATATEDRUG

Positron Emission TomographyPROCEDURE

Sponsors & collaborators

Emory Universitylead sponsor

Mapped research locations

AtlantaGeorgia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03448458 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.